此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

外科主动脉瓣置换术后心房颤动及他汀类药物的影响

2026年11月14日 更新者:Lars Peter Riber

外科主动脉瓣置换术后心房颤动和他汀类药物的影响 - 随机对照试验

Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery.

The focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF).

Our aims are: to investigate the risk of POAF, infection or other complications after SAVR in continuous versus preoperative discontinuous treatment with statins.

The study is a single centre randomized controlled trial with continuance treatment with statin vs. discontinuance (7 to 14 days prior surgery until the 30th post-operative day included), on patients undergoing elective solitary SAVR with bioprosthesis with prior usage of statins the last 3 months and of at least 7 days.

This randomized studies will address 2 separate hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that

  1. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (<30 days) risk of POAF.
  2. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (<30 days) and intermediate (<1 year) risk of mortality, MI, stroke and rehospitalisation.

研究概览

详细说明

Trial Participants:

Enrolment for the study is planned to start February 2022 and continue until 100 patients have been enrolled.

DEFINITION OF POAF:

Postoperative AF (I48) is defined as irregular RR-intervals without a traceable p-wave before each QRS complex during at least 30 seconds or entire 12-lead ECG in symptomatic or asymptomatic patients with no prior history of atrial fibrillation or flutter are considered4. Continuous ECG monitoring (8-lead ward monitor) will recognise AF during the entire hospitalization. Anamnesis, electronic health record (EHR), or confirmatory rhythm strip or 12-lead ECG of AF until 30th postoperative day are also considered.

We will also report the burden of atrial fibrillation, and treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.

Course of action:

Patients undergoing elective surgical aortic valve replacement with bioprosthesis at the Department of Cardiac Surgery at Odense University Hospital will be offered participation in the study.

Potentially eligible patients will be screened according to inclusion/exclusion criteria at the time after eligibility of surgery. This is assessed at a multidisciplinary team (MDT) conference (with attendance of cardiologist, cardiac surgeons and anaesthesiologist) based on clinical evaluation, echocardiographic ultrasound, coronary angiography and lung function test.

Patients eligible to participate in the study will be presented with the information of the study at the time of their out-patient appointment, according to normal routine at Odense University Hospital. At this appointment the patient receives a physical examination and journal record is obtained by a cardiac surgeon (approximately 7 to 14 days prior to planned surgery).

The study-information will be given by one of the participating doctors, while the patient has been informed of the possibility of bringing an assessor of their choice. The information will be delivered in a quiet room blocked to other appointments in the Department of Cardiothoracic Surgery.

During this meeting the patient will be informed of the purpose of this study and the written patient information will be submitted in detail. Patients will be given as much time as wanted after the oral information has been delivered to decide if they wish to participate in the study. Patients will be offered the possibility to call one of the doctors taking part in this study during this time, in case of additional questions. Subjects can leave the study at any time for any reason if they wish to do so, without any consequences.

Signed informed consent will be provided prior to any research procedures. A subject is registered when signed informed consent has been provided and assigned a subject identification code by the computer-generated code. A subject is randomized when a treatment and a randomisation number has been provided. A subject is considered enrolled in the study once the subject is randomized.

Patient data from EHR will be conducted according to study endpoints after signed informed consent is provided. Signed consent gives sponsor and sponsors representatives

Randomization:

Allocation to a numbered treatment pack (continuance or discontinuance of statin therapy) Randomization scheme will be set-up by OPEN data manager with control for beta-blockers and age (60-65, 66-70, 71-80, >80), and then randomization per se will be executed with the use of REDCap.

The following will be recorded at the day of randomization:

  • Conduct information for baseline characteristics
  • Transthoracic Echocardiography measurements

Collect baseline blood sample:

• Troponin, CK-MB, Creatinine, CRP

Commence intervention

Perioperative interventions and outcomes from the day of surgery to the day of discharge:

  • Duration of aortic cross clamp (ACC), extracorporeal circulation (ECC), ventilatory support, intensive care unit stay period, hospital stay period

  • Continue intervention

  • Blood samples:

    • Preoperative: Troponin, CK-MB, Creatinine, CRP, Plasma-Atorvastatin
    • Serial troponin and CK-MB levels: (6, 24, 48, and 96 hours after surgery).
    • Creatinine levels: 48 and 96 hours after surgery.
    • CRP levels: 48 and 96 hours after surgery
  • Monitor ECG by continuous Holter monitoring to commence as soon as possible after surgery and continue up to post-operative day 5 evening

  • Transthoracic Echocardiography on post-operative day 3-5

  • Record fluid intake and output during the first 48 hours following surgery based on IV fluids administration, blood transfusion (if applicable), oral/nasogastric intake, and urine plus surgical drain output

  • Record intraoperative defibrillation, removal of external pacemaker, new PPM/ICD, vasopressors, blood transfusion, surgical re-exploration, renal replacement therapy, beta-blockers, ACEi/ARB, Amiodarone, Digoxin, Diuretics, Calcium channel blockers, Potassium supplements, NSAIDs or steroids, non-study statin, use of nephrotoxic antibiotics, contrast agents or potassium sparing diuretics (Yes/No)

Assessment at/after discharge from hospital:

  • Continue study medications for 30 days after the surgery
  • Phone call on the 30th postoperative day to evaluate symptoms of discomfort compatible with atrial fibrillation
  • At the end of the study, all excess study medication can be returned at the local drugstore for safe disposal
  • Patient data from EHR will be conducted according to study endpoints.

研究类型

介入性

注册 (实际的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Odense、丹麦、5000
        • Odense University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 至 95年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients undergoing elective solitary SAVR with bioprosthesis
  2. Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other than beta-adrenergic blocking agents, at the time of surgery
  3. In treatment with HMG-CoA reductase inhibitors in the past 3 months and of at least 7 days
  4. Age >60 years
  5. Willingness and provision of informed consent to be randomized

Exclusion Criteria:

  1. Prior history of atrial fibrillation
  2. Prior history of cardiac surgery
  3. Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit)
  4. Creatinine >200 µmol/L

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Continuance

Continuance prior statin therapy.

Continuance of prior statin therapy

实验性的:Discontinuance

Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Discontinuance of prior statin therapy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants with POAF - In-hospital
大体时间:In-hospital up to 10 days.

In-hospital POAF assessed by Holter monitoring.

In-hospital up to 10 days.
Number of Participants with POAF - Early
大体时间:Early (≤30 days) incidence of POAF

Early assessed by anamnesis and electronic health record (EHR).

Early (≤30 days) incidence of POAF
Duration of POAF in-hospital
大体时间:In-hospital

Duration of POAF monitered with continuous ECG monitoring (eight-- lead ward monitor) up to 24 weeks.

In-hospital

次要结果测量

结果测量
措施说明
大体时间
Stroke - Intermediate
大体时间:Intermediate (1 year)

Number of patients with stroke in each group.

Intermediate (1 year)
Trans ischemic attack - Early
大体时间:Early (≤30 days)

Number of patients with trans ischemic attack in each group.

Early (≤30 days)
Trans ischemic attack - Intermediate
大体时间:Intermediate (1 year)

Number of patients with trans ischemic attack in each group.

Intermediate (1 year)
Myocardial infarction - Early
大体时间:Early (≤30 days)

Number of patients with Myocardial infarction in each group.

Early (≤30 days)
Myocardial infarction - Intermediate
大体时间:Intermediate (1 year)

Number of patients with Myocardial infarction in each group.

Intermediate (1 year)
Permanent pacemaker - Early
大体时间:Early (≤30 days)

Number of patients with Permanent pacemaker in each group.

Early (≤30 days)
Permanent pacemaker - Intermediate
大体时间:Intermediate (1 year)

Number of patients with Permanent pacemaker in each group.

Intermediate (1 year)
ICD implantation - Early
大体时间:Early (≤30 days)

Number of patients with ICD implantation in each group.

Early (≤30 days)
ICD implantation - Intermediate
大体时间:Intermediate (1 year)

Number of patients with ICD implantation in each group.

Intermediate (1 year)
Acute kidney injury - Early
大体时间:Early (≤30 days)

Number of patients with Acute kidney injury in each group.

Early (≤30 days)
LVEF
大体时间:Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of LVEF(left ventricular ejection fraction) between groups. Unit: %

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Strain
大体时间:Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of Strain between groups.Unit: %

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
TAPSE
大体时间:Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).

Describe echocardiography assessed differences in pre and postoperative measurements of TAPSE (tricuspid annular plane systolic excursion) between groups. Unit: mm

Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Length of stay on ICU
大体时间:Day of surgery to the day of discharge from ICU. Up to 52 weeks.

Length of stay on ICU after surgery. Unit: Days

Day of surgery to the day of discharge from ICU. Up to 52 weeks.
Number of Participants with NOAF
大体时间:Intermediate (1 year) incidence of NOAF

NOAF assessed by anamnesis and EHR.

Intermediate (1 year) incidence of NOAF
Rate of all-cause mortality - In-hospital
大体时间:In-hospital up to 10 days.

Number of deaths in each group.

In-hospital up to 10 days.
Rate of all-cause mortality - Early
大体时间:Early (≤30 days)

Number of deaths in each group.

Early (≤30 days)
Rate of all-cause mortality - intermediate
大体时间:Intermediate (1 year)

Number of deaths in each group.

Intermediate (1 year)
Myocardial injury - Tn
大体时间:After surgery until discharge up to 10 days

Injury assessed by serial Troponin measurements. Unit:ng/l

After surgery until discharge up to 10 days
Myocardial injury - CKMB
大体时间:After surgery until discharge up to 10 days

Injury assessed by serial CKMB measurements. Unit: μg/l.

After surgery until discharge up to 10 days
Stroke - Early
大体时间:Early (≤30 days).

Number of patients with stroke in each group.

Early (≤30 days).
Length of stay in hospital
大体时间:Day of surgery to the day of discharge from the hospital. Up to 52 weeks.

Length of stay in hospital after surgery. Unit: Days

Day of surgery to the day of discharge from the hospital. Up to 52 weeks.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年4月1日

初级完成 (实际的)

2026年10月1日

研究完成 (实际的)

2026年10月1日

研究注册日期

首次提交

2021年8月19日

首先提交符合 QC 标准的

2021年9月29日

首次发布 (实际的)

2021年9月30日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月14日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • STARC210421_3
  • 2021-002210-13 (EudraCT编号)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Data will be available in anonymized form in accordance with GDPR upon reasonable request.

Rules for external researchers to apply for and access data will be laid out towards the end of the study.

IPD 共享时间框架

TBA

IPD 共享访问标准

TBA

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅